Abstract: A model that closely resembles human excessive myopia can be prepared by mounting a minus lens (2) and a protector (4) to a juvenile mouse, the minus lens having an angle and a width adjustable in response to growth of the mouse. Further, this model analysis shows that myopia induction causes endoplasmic reticulum stress in a sclera and the endoplasmic reticulum stress induces myopia. Furthermore, it is revealed that an endoplasmic reticulum stress suppressant, particularly, phenylbutyrate and tauroursodeoxycholic acid act as a myopia prevention/suppression agent.

Abstract: To provide a display system such as a smartphone, a game console, a personal computer, or a liquid crystal television, including a light-emitting element that irradiates light having a specific wavelength toward a user. The above-described problem is solved by a display system (1) including a first light-emitting element (6) that emits light used for image display, a second light-emitting element (3) that irradiates light (7) within a wavelength range of 360 nm to 400 nm, inclusive, toward a user, and a control unit (10) that controls irradiation of the light (7) from the second light-emitting element (3). At this time, the second light-emitting element (3) may be a single light-emitting element integrated with the first light-emitting element (6) or a light-emitting element provided separately from the first light-emitting element (6).

Abstract: A lottery device includes: a drawing body having medium entrance units which are provided along a circumferential direction thereof, and into each of which a game medium can enter; a driving mechanism driving the drawing body in the circumferential direction; a dividing device dividing a periphery of a path of the medium entrance units, in which path the medium entrance units travel, into lottery segments in the circumferential direction; a medium introduction mechanism introducing the game medium individually into each lottery segment; an entrance unit detection device detecting a medium entrance unit into which the game medium has entered; a displacement amount detection device detecting an amount of displacement in the circumferential direction; and a lottery segment distinguishing device distinguishing from which of the lottery segments the game medium has entered into the medium entrance unit based on a result of detection by the displacement amount detection device.

Abstract: The problem of the present invention is to provide a method of efficiently producing therapeutic alternative corneal endothelial cells, particularly, a method capable of stably producing them in a condition suitable for intraocular transplantation (in the anterior chamber) in a large amount. Furthermore, the present invention aims to provide a composition for transplantation, which is preferable for intraocular administration, particularly, into the anterior chamber. A therapeutic alternative corneal endothelial cell sphere can be produced by culturing stem cells in suspension in a differentiation induction medium containing a GSK3 inhibitor, retinoic acid and a ROCK inhibitor. Addition of a viscoelastic substance during intraocular (into the anterior chamber) transplantation of the sphere or cultured corneal endothelial cells dispersed into single cells can increase the number of adherent cells after transplantation.

Abstract: Novel HIF inhibitors having low cytotoxicity and suitable for ophthalmologic treatment and agents for the treatment or prevention of ischemic diseases, glaucoma, optic nerve diseases, retinal degenerative diseases, retinal degenerative diseases, angiogenic retinal diseases, cancer, neurodegenerative or autoimmune diseases are provided. The present invention is a therapeutic or prophylactic agent for ischemic disease, glaucoma, optic nerve disease, retinal degenerative disease, retinal degenerative disease, angiogenic retinal disease, cancer, neurodegenerative disease, or autoimmune disease, which comprises as an active ingredient one or more or an extract thereof selected from the group consisting of plants belonging to the genus Asian, plants belonging to the genus Swiss, plants belonging to the genus Grape, plants belonging to the genus Brassica, fish belonging to the genus Kivinago, and so on.

Abstract: The purpose of the present invention is to provide an agent for restoring a visual function or an agent for preventing the deterioration in a visual function, which has an excellent visual function restoring ability. The agent for regenerating a visual function or the agent for preventing the deterioration in a visual function according to the present invention contains, as an active ingredient, a chimeric protein having both an amino acid sequence for a microorganism-origin ion-transporting receptor rhodopsin and an amino acid sequence for an animal-origin G-protein-coupled receptor rhodopsin. The chimeric protein is preferably one in which an amino acid sequence for a cytoplasm-side second loop and/or a cytoplasm-side third loop in the amino acid sequence for the microorganism-origin ion-transporting receptor rhodopsin is substituted by an amino acid sequence for a cytoplasm-side second loop and/or a cytoplasm-side third loop in the G-protein-coupled receptor rhodopsin.

Abstract: Provided are a novel therapeutic or prophylactic agent for graft-versus-host disease, a novel agent for inhibiting fibrocyte infiltration, and a novel agent for inhibiting a decrease in tear secretion and a decrease of goblet cells. A method of treating or preventing graft-versus-host disease comprises administering a phenylbutyric acid or a pharmacologically acceptable salt thereof to a patient in need of treatment or prevention of graft-versus-host disease. It is preferable that the graft-versus-host disease be a graft-versus-host disease that manifests after bone marrow transplantation. It is preferable that the graft-versus-host disease be ocular graft-versus-host disease.

Abstract: The purpose of the present invention is to provide a myopia treatment device. A myopia treatment device of the present invention comprises a light transmission part selected from a group consisting of an eyesight correcting tool, an eye protection tool, a face protection tool, a sunshade, a display device, a window, a wall, a light source covering, and a coating material. The light transmission part of the device transmits violet light having a wavelength within a range of 360 nm to 400 nm inclusive and thus treats myopia. Or, the myopia treatment device comprises a light emission part selected from a group consisting of lighting equipment, a display device, and a light irradiation device. The light emission part of the device emits violet light having a wavelength within a range of 360 nm to 400 nm inclusive and thus treats myopia.

Abstract: The present invention provides foods and beverages comprising a combination of two or more digestion-resistant components. This invention also provides an agent for producing hydrogen gas in the large intestine, the agent comprising a combination of two or more digestion-resistant components. The foods and beverages or the agent for producing H2 in the large intestine according to this invention can induce sustained production of large amounts of hydrogen gas by intestinal bacteria of more human individuals.

Abstract: To provide a translucent member that has the effect of lowering triglycerides, increasing IRS-2, and the like. The above-described problem is solved by a translucent member (1) that blocks or suppresses transmission of at least light that is received by an eye and has a wavelength of 460 nm. The translucent member (1) may be an eyeglass lens or eyeglasses as a whole. The eyeglasses (1) preferably comprise a lens (2) that blocks or suppresses transmission of at least light having a wavelength of 460 nm, and a rim (3) that blocks or suppresses transmission of at least light having a wavelength of 460 nm. The rim (3) preferably comprise a projecting portion (3a) for decreasing a gap between the rim (3) and a face of an eyeglass wearer or eliminating the gap by coming into contact with the face.

Abstract: A light source for myopia prevention article includes a light emitter to emit light having an emission spectrum continuing from a first wavelength of not less than 360 nm nor more than 400 nm to a second wavelength of more than 400 nm.

Abstract: A lottery device includes: a drawing body having medium entrance units which are provided along a circumferential direction thereof, and into each of which a game medium can enter; a driving mechanism driving the drawing body in the circumferential direction; a dividing device dividing a periphery of a path of the medium entrance units, in which path the medium entrance units travel, into lottery segments in the circumferential direction; a medium introduction mechanism introducing the game medium individually into each lottery segment; an entrance unit detection device detecting a medium entrance unit into which the game medium has entered; a displacement amount detection device detecting an amount of displacement in the circumferential direction; and a lottery segment distinguishing device distinguishing from which of the lottery segments the game medium has entered into the medium entrance unit based on a result of detection by the displacement amount detection device.

Abstract: An optical element has a transmission spectrum characterized in that a local maximum falls within a wavelength region longer than 315 nm but shorter than or equal to 400 nm, a local minimum falls within a wavelength region longer than or equal to 380 nm but shorter than or equal to 500 nm, and the wavelength at the local maximum is shorter than the wavelength at the local minimum.

Abstract: The purpose of the present invention is to provide a myopia prevention device. A myopia prevention device of the present invention comprises a light transmission part selected from a group consisting of an eyesight correcting tool, an eye protection tool, a face protection tool, a sunshade, a display device, a window, a wall, a light source covering, and a coating material. The light transmission part of the device transmits light having a wavelength within a range of 350 nm to 400 nm inclusive and thus suppresses the occurrence and progression of myopia. Further, a myopia prevention device comprises a light emission part selected from a group consisting of lighting equipment, a display device, and a light irradiation device. The light emission part of the device emits light having a wavelength within a range of 350 nm to 400 nm inclusive and thus suppresses the occurrence and progression of myopia.

Abstract: A wavelength-selective transmissive glass has a light transmittance Tmore than 315 nm and 400 nm or less at a wavelength of more than 315 nm and 400 nm or less represented by the formula shown below of 1% or more in terms of a plate thickness of 6 mm and a light transmittance T315 nm or less at a wavelength of 315 nm or less represented by the formula shown below of 60% or less in terms of a plate thickness of 6 mm. Ak is a weighting factor at a wavelength k (nm) for calculating T (light transmittance) defined in ISO-9050:2003, and Tk is a transmittance at the wavelength k (nm) in terms of a plate thickness of 6 mm: Tmore than 315 nm and 400 nm or less=(?k=more than 315400 Ak×Tk)/(?k=more than 315400 Ak) T315 nm or less=(?k=300315 Ak×Tk)/(?k=300315 Ak).

Abstract: To provide an irradiation device capable of preventing myopia or slowing the progression of myopia by the action of light irradiated toward the eyeball. An irradiation device (10) comprises a light source (1) and an instrument (2) on which the light source (1) is mounted. The light source (1) emits at least light having a wavelength within a range of 350 to 400 nm, inclusive, and is disposed in a position that allows irradiation in an eyeball direction when the instrument (2) is mounted. Further, the light source (1) is disposed in a position 0 to 100 mm, inclusive, from a surface of the eyeball. At this time, an irradiance of the light having a wavelength within the range of 350 to 400 nm, inclusive, is 0.02 to 1.0 W/m2, inclusive, on the eyeball surface when the instrument (2) is worn.

Abstract: A wavelength-selective transmissive glass article has light transmittance Tmore than 315 nm and 400 nm or less at a wavelength of more than 315 nm and 400 nm or less of 1% or more. In addition, the wavelength-selective transmissive glass article has light transmittance T315 nm or less at a wavelength of 315 nm or less of 60% or less.

Abstract: A pharmaceutical composition for prophylaxis and/or treatment of a corneal and conjunctival disease or presbyopia, the composition containing a compound represented by Formula (I), or a salt thereof or a prodrug thereof as an active ingredient, wherein m and n are each independently an integer of 0 to 5; m+n?1; and each aromatic ring of the compound represented by Formula (I) may be substituted.

Abstract: This invention provides a prophylactic and therapeutic agent for dry eye, having new ingredients to reduce the deterioration of the lacrimal secretory ability and to inhibit the generation of radical oxygen in lacrimal gland tissue. The prophylactic and therapeutic agent for dry eye of this invention contains the maqui berry extract as the active substance of this invention, i.e. containing delphinidin glycoside extracted from the maqui berry and at least one or more of the active substances delphinidin-3-sambubioside-5-glucoside, delphinidin-3,5-diglucoside, delphinidin-3-sambubioside and delphinidin-3-glucoside, preferably delphinidin-3,5-diglucoside.

Abstract: The present invention aims to provide an agent for treating meibomian gland dysfunction. The present invention provides an agent for treating meibomian gland dysfunction, which contains activated vitamin D3 or a derivative thereof as an active ingredient.